fbpx

Year

2012
  BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced today that it has been selected as a Top 100 Winner for Red Herring's 2012 Europe Award, a prestigious list honoring the year's most promising private technology ventures from the European business region....
  Lund, SWEDEN, BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic replacement surgeries, today announced the appointment of Andreas Muchowski to the position of Vice President of Sales Germany. Andreas will lead sales recruiting efforts and prepare for the upcoming market launch of exciting...
Sunnyvale, CA, Asante Solutions, Inc. (Asante), a medical device company focused on diabetes care, has strengthened its leadership team by adding David Thrower as president and chief executive officer, and Eric Steuben as vice president of operations. Former President and Chief Executive Officer Phil Hopper will remain as a special advisor and board member.  ...
LUND, Sweden, April 4, 2012 /PRNewswire/   BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgeries, today revealed details of a One Hundred Day Plan presented by Chief Executive Officer Lloyd Diamond. Mr. Diamond addresses key initiatives aimed at accelerating global commercialization of the...
BURLINGTON, MA (April 2, 2012): AlloCure, Inc., a clinical stage biotechnology company focused on the treatment of kidney disease, today announced the closing of a $25 million Series B venture financing. The round included the participation of new syndicate member Lundbeckfond Ventures, as well as previous investors SV Life Sciences and Novo A/S. AlloCure also...
  Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that enrolment has been completed in its pivotal LCP-Tacro Phase III study in de novo kidney transplant patients. The LCP-Tacro 3002 study is designed to demonstrate non-inferiority versus the gold standard therapy Prograf® and has randomized over 540 patients at approximately 90 clinical sites around the world....
BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced the launch of a new corporate web site. The new web site aims to update the BONESUPPORT brand while providing increased educational and clinical CERAMENTT content to an expanding audience. “Our business has...
Funding enables further development of unique metagenomic technology and solutions for gut microbiota-related diseases affecting a large proportion of world populationParis, March 22, 2012 – Enterome, a stratified medicine company developing biomarkers for chronic and challenging medical conditions relating to abnormalities of bacterial composition of the human intestine (metabolic and bowel diseases), today announces a...
Causes for mental disorders will now be thoroughly investigated. A new grant - the largest sum ever awarded to a Danish research team in this field - will support Danish researchers in their pursuit of understanding mental disorders. The project may also lead to new prevention and treatment methods.
1 2 3 4 5

News

Maude has become the stereotypical migraine patient – but it’s not quite the true picture
31. July 2020
Ancient DNA throws a ‘scientific hand grenade’ into the discussion about the arrival of humans in North America
23. July 2020
Danish researchers map key disease mechanism – and describe a completely new protein
20. July 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge